Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy

Lancet

Volumn 347, Issue 9009, 1996, Pages 1151-1155

  Habib, Farida M ^a   Springall, David R ^a,c   Davies, Graham J ^a   Oakley, Celia M ^a   Yacoub, Magdi H ^b   Polak, Julia M ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

^c RPMS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; NITRIC OXIDE SYNTHASE;

ARTICLE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; HEART CONTRACTION; HEART MUSCLE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOPHYSIOLOGY; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOCARDIUM; ENZYME INDUCTION; HEART DILATATION; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HISTOCHEMISTRY; HUMAN TISSUE; IMAGE ANALYSIS; INOTROPISM; ISCHEMIC HEART DISEASE; OPTICAL DENSITY; PATHOGENESIS; PRIORITY JOURNAL; RISK; SMOOTH MUSCLE FIBER; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

CARDIOMYOPATHY, DILATED; CORONARY DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030603619     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)90610-8     Document Type: Article

References (30)

1. Muntoni F, Cau M, Ganau A, et al. Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. N Engl J Med 1993; 329: 921-25.
2. Bowles NE, Richardson PJ, Olsen EG, Archard LC. Detection of Coxsackie-B-virus-specific RNA sequences in myocardial biopsy samples from patients with myocarditis and dilated cardiomyopathy. Lancet 1986; i: 1120-23.
3. Caforio AL, Bonifacio E, Stewart JT, et al. Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. J Am Coll Cardiol 1990; 15: 1527-34.
4. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
5. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323: 236-41.
6. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 1991; 66: 356-58.
7. Katz SD, Schwarz M, Yuen J, Le Jemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993; 88: 55-61.
8. Drexler H, Hayoz D, Munzel T, Just H, Zelis R, Brunner HR. Endothelial function in congestive heart failure. Am Heart J 1993; 126: 761-64.
9. Habib F, Dutka D, Crossman D, Oakley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure: another failed counter-regulatory vasodilator mechanism? Lancet 1994; 344: 371-73.
10. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 1994; 89: 955-58.
11. Kroncke K-D, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol Chem Hoppe-Seyler 1995; 376: 327-43.
12. de Belder AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium. Lancet 1993; 341: 84-85.
13. McBride JT. Quantitative immunocytochemistry. In: Wootton R, Springall DR, Polak JM, eds. Image analysis in histology: conventional and confocal microscopy. Cambridge: Cambridge University Press, 1995.
14. Bowles NE, Rose ML, Taylor P, et al. End-stage dilated cardiomyopathy. Persistence of enterovirus RNA in myocardium at cardiac transplantation and lack of immune response. Circulation 1989; 80: 1128-36.
15. Latif N, Baker CS, Dunn MJ, Rose ML, Brady P, Yacoub MH. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol 1993; 22: 1378-84.
16. Arbustini E, Gavazzi A, Pozzi R, et al. The morphologic spectrum of dilated cardiomyopathy and its relation to immune-response genes. Am J Cardiol 1989; 64: 991-95.
17. Woodruff JF. Viral myocarditis. A review. Am J Pathol 1980; 101: 425-84.
18. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL. Tumour necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 1995; 96: 1042-52.
19. Seko Y, Matsuda H, Kato K, et al. Expression of intercellular adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3. J Clin Invest 1993; 91: 1327-36.
20. Munkvad S, Gram J, Jespersen J. Interleukin-1 and tumor necrosis factor-alpha in plasma of patients with acute ischemic heart disease who undergo thrombolytic therapy: a randomized, placebo-controlled study. Lymphokine Cytokine Res 1991; 10: 325-27.
21. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumour necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487-93.
22. Walley KR, Hebert PC, Wakai Y, Wilcox PG, Road JD, Cooper DJ. Decrease in left venticular contractility after tumor necrosis factor-alpha infusion in dogs. J Appl Physiol 1994; 76: 1060-67.
23. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303-12.
24. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-89.
25. Ungureanu-Longrois D, Balligand JL, Simmons WW, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to beta-adrenergic agonists. Circ Res 1995; 77: 494-502.
26. Yoshizumi M, Perrella MA, Burnett JC Jr, Lee ME. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993; 73: 205-09.
27. Kirchhofer D, Tschopp TB, Hadvary P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest 1994; 93: 2073-83.
28. Dunkman WB, Johnson GR, Carson PE, Bhat G, Farrell L, Cohn JN. Incidence of thromboembolic events in congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI94-101.
29. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992; 105: 575-80.
30. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ. The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta. J Clin Invest 1995; 95: 677-85.